3 Stocks Moving The Drugs Industry Upward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 7 points (0.0%) at 17,628 as of Monday, Nov. 17, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,137 issues advancing vs. 1,826 declining with 176 unchanged.

The Drugs industry currently sits up 0.1% versus the S&P 500, which is down 0.2%. Top gainers within the industry include Celldex Therapeutics ( CLDX), up 30.9%, Regeneron Pharmaceuticals ( REGN), up 2.0%, Mylan ( MYL), up 1.9%, Sanofi ( SNY), up 1.4% and Teva Pharmaceutical Industries ( TEVA), up 1.0%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Amgen ( AMGN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Amgen is up $1.04 (0.7%) to $158.72 on light volume. Thus far, 989,190 shares of Amgen exchanged hands as compared to its average daily volume of 3.8 million shares. The stock has ranged in price between $156.66-$160.20 after having opened the day at $156.91 as compared to the previous trading day's close of $157.68.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Amgen has a market cap of $122.4 billion and is part of the health care sector. Shares are up 38.2% year-to-date as of the close of trading on Friday. Currently there are 7 analysts who rate Amgen a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, solid stock price performance, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Amgen Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Merck ( MRK) is up $0.40 (0.7%) to $59.48 on light volume. Thus far, 3.7 million shares of Merck exchanged hands as compared to its average daily volume of 10.3 million shares. The stock has ranged in price between $59.31-$59.90 after having opened the day at $59.69 as compared to the previous trading day's close of $59.07.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $169.7 billion and is part of the health care sector. Shares are up 18.0% year-to-date as of the close of trading on Friday. Currently there are 6 analysts who rate Merck a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Merck Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, AbbVie ( ABBV) is up $1.16 (1.8%) to $65.16 on light volume. Thus far, 2.8 million shares of AbbVie exchanged hands as compared to its average daily volume of 13.3 million shares. The stock has ranged in price between $64.03-$65.22 after having opened the day at $64.10 as compared to the previous trading day's close of $64.00.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. AbbVie has a market cap of $101.4 billion and is part of the health care sector. Shares are up 21.2% year-to-date as of the close of trading on Friday. Currently there are 7 analysts who rate AbbVie a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates AbbVie as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and weak operating cash flow. Get the full AbbVie Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Stocks Lose Steam as Yields Hover Near 3% Threshold

Stocks Lose Steam as Yields Hover Near 3% Threshold

Video: Stop Using Student Loan Money to Buy Bitcoin

Video: Stop Using Student Loan Money to Buy Bitcoin

Let the Najarian Brothers Crash-Proof Portfolio

Let the Najarian Brothers Crash-Proof Portfolio

Facebook Sends Facial Recognition Notification in Error

Facebook Sends Facial Recognition Notification in Error

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists